The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Entrada Therapeutics Inc shares valued at $781,638 were purchased by BAKER BROS. ADVISORS LP on Nov 12 ’25. At $7.76 per share, BAKER BROS. ADVISORS LP acquired 100,736 shares. The insider’s holdings grew to 4,664,924 shares worth approximately $40.96 million following the completion of this transaction.
Also, BAKER BROS. ADVISORS LP purchased 46,434 shares, netting a total of over 348,193 in proceeds. Following the buying of shares at $7.50 each, the insider now holds 4,572,549 shares.
Before that, BAKER BROS. ADVISORS LP had added 30,874 shares to its account. In a trade valued at $222,756, the 10% Owner bought Entrada Therapeutics Inc shares for $7.21 each. Upon closing the transaction, the insider’s holdings increased to 30,874 shares, worth approximately $39.77 million.
As published in their initiating research note from ROTH MKM on December 06, 2024, Entrada Therapeutics Inc [TRDA] has been a Buy and the price target has been revised to $29. Analysts at Oppenheimer started covering the stock with ‘”an Outperform”‘ outlook in a report released in early January. As of April 03, 2023, H.C. Wainwright has initiated its “Buy” rating for TRDA.
Analyzing TRDA Stock Performance
On last trading session, Entrada Therapeutics Inc [NASDAQ: TRDA] rose 9.61% to $8.78. The stock’s lowest price that day was $8.0755, but it reached a high of $9.125 in the same session. During the last five days, there has been a surge of approximately 26.33%. Over the course of the year, Entrada Therapeutics Inc shares have dropped approximately -55.86%. Shares of the company reached a 52-week high of $18.76 on 01/03/25 and a 52-week low of $4.93 on 08/11/25.
Support And Resistance Levels for Entrada Therapeutics Inc (TRDA)
According to the 24-hour chart, there is a support level at 8.20, which, if violated, would cause prices to drop to 7.61. In the upper region, resistance lies at 9.24. The next price resistance is at 9.71. RSI (Relative Strength Index) is 78.18 on the 14-day chart, showing overbought technical sentiment.
Is Entrada Therapeutics Inc subject to short interest?
Stocks of Entrada Therapeutics Inc saw a sharp rise in short interest on 2025-10-31 jumping by 80397.0 shares to 0.89 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 0.81 million shares. A jump of 9.0% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.94 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.94.
Which companies own the most shares of Entrada Therapeutics Inc (TRDA)?
In terms of Entrada Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 13 in the next 12 months, up nearly 62.3% from the previous closing price of $8.01. Analysts anticipate Entrada Therapeutics Inc stock to reach 13 by 2025, with the lowest price target being 13. In spite of this, 3 analysts ranked Entrada Therapeutics Inc stock as Buy at the end of 2025.
